$-0.14
(Market cap
$5 Mln
Revenue (TTM)
$9 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-8.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-25.7
-
Face value
--
-
Shares outstanding
1,666,100
6 Years Aggregate
CFO
$-337.95 Mln
EBITDA
$-413.24 Mln
Net Profit
$-421.77 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bioatla Inc (BCAB)
| -89.0 | -7.4 | -15.4 | -82.5 | -70.5 | -72.7 | -- |
|
BSE Sensex*
| -8.3 | 2.1 | 2.2 | -3.9 | 6.2 | 6.8 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Bioatla Inc (BCAB)
| -4.0 | -75.7 | -70.2 | -58.0 | -42.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bioatla Inc (BCAB)
|
3.1 | 5.3 | 8.5 | -31.5 | -345.7 | -- | -- | 2.7 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 359.8 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Bioatla Inc (BCAB)
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a... conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California. Read more
-
Co-Founder, CEO & Chairman
Dr. Jay M. Short Ph.D.
-
Co-Founder, CEO & Chairman
Dr. Jay M. Short Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Bioatla Inc (BCAB)
What is the current share price of Bioatla Inc (BCAB) Today?
The share price of Bioatla Inc (BCAB) is $3.12 (NASDAQ) as of 26-Aug-2026 16:00 EDT. Bioatla Inc (BCAB) has given a return of -70.5% in the last 3 years.
What is the current PB & PE ratio of Bioatla Inc (BCAB)?
Since, TTM earnings of Bioatla Inc (BCAB) is negative, P/E ratio is not available.
The P/B ratio of Bioatla Inc (BCAB) is 2.68 times as on 21-Aug-2026, a 50 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.01 |
-0.02 |
2024 |
-0.01 |
0.04 |
2023 |
-0.02 |
0.03 |
2022 |
-0.07 |
0.04 |
2021 |
-0.14 |
0.06 |
What is the 52 Week High and Low of Bioatla Inc (BCAB)?
The 52-week high and low of Bioatla Inc (BCAB) are Rs 71.50 and Rs 2.81 as of 27-Aug-2026.
What is the market cap of Bioatla Inc (BCAB)?
Bioatla Inc (BCAB) has a market capitalisation of $ 5 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bioatla Inc (BCAB)?
Before investing in Bioatla Inc (BCAB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.